Search Results - therapeuticarea+%3e+infectious+disease

503 Results Sort By:
Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition
This technology includes a new class of nanobody–antiviral peptide conjugates that block HIV from infecting human CD4⁺ T-cells, positioning them for future therapeutic and prophylactic use. Nanobodies—single-domain antibody fragments—guide the drug to the virus’s docking site and impede receptor binding, while the linked peptide...
Published: 5/14/2025   |   Inventor(s): Ross Cheloha, Shubhra Saha
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Reproductive Health
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance...
Published: 5/8/2025   |   Inventor(s): Sarah Andrews, Grace Mantus, Ankita Chopde, Adrian Creanga, Rebecca Gillespie, Masaru Kanekiyo, Julie Raab
Keywords(s):  
Category(s): Application, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, ResearchProducts > Antibodies, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology
A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease. The primary...
Published: 5/8/2025   |   Inventor(s): Patrick Duffy, Jonathan Renn
Keywords(s):  
Category(s): Application, Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, ResearchProducts > Sequences, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases.
Treatment for human tuberculosis (TB) and other granulomatous diseases would benefit from high- throughput screening (HTS)-compatible platform replicating physiological conditions in hallmark granuloma lesions. However, currently available screening platforms and 2-D and 3-D cell culture systems lack throughput and key features, and relevant microenvironments...
Published: 5/9/2025   |   Inventor(s): Suraj Sable, James Posey, Wen Li, Allison Kline
Keywords(s):  
Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract
This technology includes a Drosophila mutant strain that can be used as an in vivo model for diseases of the oral cavity and digestive tract (Sjogren's syndrome, colitis, colon cancer, inflammatory bowel disease), where the mucous membrane is disrupted or non-functional. This mutant lacks a mucous membrane and displays epithelial cell damage, uncontrolled...
Published: 12/26/2024   |   Inventor(s): Liping Zhang, Kelly Ten Hagen
Keywords(s): FUNCTIONS, IDENTIFY, Inhibitors, Interrogate, Jak/STAT, MEMBRANES, MIMETICS, Mucin/glycan, Mucous, System, Vivo, VPXXXX, WIXXXX, XEXXXX
Category(s): TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Cardiology
Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery
This technology includes the NeurEx® mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app's robust design...
Published: 12/10/2024   |   Inventor(s): Cyril Le Nouen, Joseph Marcotrigiano, Ursula Buchholz, Peter Collins
Keywords(s):  
Category(s): Application > Research Materials, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease
Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development
The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified...
Published: 5/16/2025   |   Inventor(s): Suzanne Emerson, Hanh Nguyen, Udana Torian
Keywords(s):  
Category(s): Application > Research Materials, ResearchProducts, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease
A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics
BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome...
Published: 12/10/2024   |   Inventor(s): Ursula Buchholz
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
A Key Advancement for Human Norovirus Research and Reverse Genetics
The HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which...
Published: 12/10/2024   |   Inventor(s): Carlos Sandoval-Jaime, Stanislav Sosnovtsev
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases
Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent...
Published: 12/10/2024   |   Inventor(s): Zhao Chun Chen, Robert Purcell, Mahtab Moayeri, Stephen Leppla
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
1 2 3 4 5 6 7 8 9 10 ...